Kailera Therapeutics (NASDAQ:KLRA) Shares Gap Up – Should You Buy?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price gapped up prior to trading on Friday . The stock had previously closed at $20.99, but opened at $21.91. Kailera Therapeutics shares last traded at $20.53, with a volume of 116,954 shares.

Analysts Set New Price Targets

KLRA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target for the company. Jefferies Financial Group started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target on the stock. TD Cowen initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target for the company. Evercore initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, Wall Street Zen cut Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 6.1%

Insiders Place Their Bets

In other news, major shareholder Rtw Investments, Lp bought 500,000 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the transaction, the insider directly owned 10,776,820 shares in the company, valued at approximately $172,429,120. This trade represents a 4.87% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. This represents a 47.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 10,460,938 shares of company stock worth $167,375,008 in the last ninety days.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.